Novartis Presentations at SABCS 2022
As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
Abstract # P4-09-12
Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B
Abstract # P5-02-32
Differential Gene Mutation Landscape in Patients With PIK3CA-altered and Non-altered Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer in the SOLAR-1 Clinical Trial
Abstract # PD13-06
Long-Term and Very-Long-Term Disease Control in Patients from BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer
H. S. Rugo
Abstract # GS1-10
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Y.S. Lu
Abstract # OT2-19-01
Single cell characterization of longitudinal biopsies from breast cancer patients treated neoadjuvantly with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib in concert
M. Fongård
Abstract # P1-02-01
Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: a systematic review and trial-level meta-analysis
W. Janni
Abstract # P3-03-12
Risk of recurrence with adjuvant endocrine therapy in real-world patients with hormone receptor positive/human epidermal growth factor receptor–negative early breast cancer: a US database analysis
J. O’Shaughnessy
Abstract # P4-01-01
RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2– ABC
C. Jackisch
Abstract # P4-01-03
Progression-free survival and patient-reported outcomes in HR+, HER2– ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA
P. A. Fasching
Abstract # P4-01-05
Machine learning to predict treatment response and tolerability in HR+, HER2– advanced breast cancer: German study AI4ANNA
P. A. Fasching
Abstract # P4-01-42
Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer in the MONALEESA-2, -3, and -7 studies
E. Hamilton
Abstract # P5-02-14
Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
J. Andre
Abstract # PD17-08
Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2, -3, and -7 trials
A. Bardia
Abstract # PD17-12
Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer
F. Cardoso
